Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Recruiting now · Phase 3

Conditions studied: Histiocytosis

In brief

Prospective, low intervention, open, single-center, non-commercial clinical trial to improve diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor tissues, monitoring its presence in free-circulating DNA, and determining the efficacy of fluorodeoxyglucose (18F-FDG) in PET-CT imaging.

Key facts

Study ID

NCT04943211

Run by

Anna Raciborska

People needed

150

Starts

2021-04-01

Expected to finish

2027-06-30

Last updated by the study team

2026-03-25

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient under 18 years of age at the time of inclusion.
• Histopathologically confirmed or suspected histiocytosis (based on prior test results).
• Signing of informed consent for trial participation according with current legal regulations.

You may not qualify if…

• Lack of inclusion criteria.
• Pregnancy.
• Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.

Where it is running

• Mother and Child Institute — Warsaw, Mazovian, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.